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Background: In Ethiopia, the publicly funded antiretroviral 
treatment (ART) program was started in 2005.  Two hundred 
seventy-five thousand patients were enrolled in the national ART 
program by 2012. However, there is limited data on mortality and 
predictors of death among adult patients in the ART program. The 
study aimed to estimate mortality and risk factors for death among 
adult, ART-naïve patients, started in the national ART program 
from January 2009 to July 2013. 
Methods: Multi-site, prospective, observational cohort study of 
adult, age > 18 years, ART-naïve patients, started in the national 
ART program at seven university-affiliated hospitals from January 
2009 - July 2013. Kaplan-Meier and Cox regression analyses were 
used to estimate survival and determine risk factors for death. 
Results: A total of 976 patients, 594 females (60.9 %), were 
enrolled into the study. Median age of the cohort was 33years.  The 
median CD4 count at start of ART was 144 cells/µl (interquartile 
range (IQR) 78-205), and 34.2% (330/965) had CD4 < 100. Sixty-
three percent (536/851) had viral load greater than 5 log copies/ml 
(IQR 4.7-5.7) at base line. One hundred and one deaths were 
recorded during follow-up period, all-cause mortality rate 10.3%; 
5.4 deaths/100 person years of observation, 95% confidence 
interval 4.4-6.5. Seventy percent of the deaths occurred within six 
months of starting ART. Cox regression analyses showed that the 
following measures independently predicted mortality: age >51 
years, (Adjusted Hazard Ratio (AHR) 4.01, P=0.003), WHO stages 
III&IV, (AHR 1.76, p = 0.025), CD4 count, <100, (AHR 2.36, p 
=0.006), and viral load >5 log copies /ml (CHR 1.71, p = 0.037).   
Conclusion: There is high early on- ART mortality in patients 
presenting with advanced immunodeficiency. Detecting cases and 
initiating ART before onset of advanced immunodeficiency might 
improve survival. 
Key Words: Ethiopia, HIV clinical cohort, Antiretroviral therapy, 
Survival 
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Several studies from both developed and low-
income countries have demonstrated the survival 
benefits of anti-retroviral therapy, ART, (1-10). 
Although treatment effectiveness as measured by 
CD4 increase or viral suppression is similar 
between developed and low-income countries, there 
is greater than threefold increase in early mortality 
in resource-poor settings (3-7). In a meta-analysis of 
survival from 18 ART programs in sub-Saharan 
Africa, early mortality, within 12 months after start 
of ART, of 8% to 26% has been reported(8). Male 
sex, older age, advanced World Health Organization 
(WHO) clinical stages, low hemoglobin, and low 
CD4 counts, at baseline were independent risk 
factors for death (8). A meta-analysis that compared 
mortality among low- and middle-income countries 
reported that sub-Saharan Africa had the highest 12-
month mortality probability of 17%, compared to 
11% for Asia, and 7% for the Americas (10).  
The publicly funded ART program in Ethiopia was 
started in 2005. By 2012, 275,000 people living 
with human immunodeficiency virus (PLHIV), 65% 
of whom were eligible for treatment, were in the 
national ART program. However, there are few 
studies that reported mortality rate of patients in the 
national ART program (11-14). Furthermore, the 
available studies were conducted at the beginning of 
the ART roll-out, estimates were based on small 
numbers of patients and short follow-up time (12), 
and were from single or two treatment sites (13, 
14); thus limiting their generalizability.  
The present study overcame these limitations by 
recruiting large number of patients from seven 
country-wide sites, and followed them for up to 
three years. The aim was to estimate mortality and 
risk factors for death among adult ART-naïve 
patients in the national ART program, and to inform 




Study design: Prospective, multi-site, observational 
cohort of previously untreated adult HIV-infected 
patients older than 18 years of age who started on 
ART in the national ART program from January 
2009 - July 2013 as a sub-set of the advanced 
clinical monitoring cohort.  
Setting:  Seven university-affiliated hospitals in 
country-wide urban settings. Treatment sites were 
the Armed Forces and Tikur Anbessa Teaching 
Hospitals in Addis Ababa; Hiwot Fana Specialized 
Hospital in Harar, Harari Region; Gondar 
University Hospital in Gondar, Amhara Region; 
Jimma Specialized Referral Hospital in Jimma, 
Oromia Region; Hawassa Univerisry Referral 
Hospital in Hawassa, Southern Nations and 
Nationality People Region; and Mekelle Referral 
Hospital in Mekelle, Tigray Region.   
Measurements: Socio-demographic characteristics 
including age, sex, marital status, type of health 
facility and level of education; and clinical 
parameters such as WHO clinical stage, functional 
status, diagnosis and treatment for tuberculosis 
(TB), cotrimoxazole prophylaxis (CPT) status, 
isoniazid preventive therapy (INH) and laboratory 
tests, including blood samples for pre-treatment 
CD4 count and viral load determination were 
collected, and results recorded in standardized 
national ART intake and follow-up forms.  
Viral load (VL) determination was done in a 
reference laboratory at the Ethiopian Public Health 
Institute (EPHI). NucliSENS easyQ
®
 HIV-1 Nucleic 
Acid Sequence-Based-Amplification (NASBA) 
assay (BioMérieux Diagnostics) was employed to 
determine VL in patients’ plasm samples. CD4 
count was determined using BD FACSCalibur 
machines (Becton Dickinson, San Jose, USA). The 
CD4 tests were done at laboratories within the 
participating health facilities using patients’ 
uncoagulated whole blood. Quality of tests were 
ensured through employing internal quality control 
and external quality assurance systems.   
Interventions: Eligibility for ART was according 
to the 2007 Ethiopian Guideline on ART (15). 
Indications for treatment were WHO clinical stages 
III/IV or CD4 < 200 cells/µl. Treatment consisted of 
two nucleoside analogues, azidothymidine (AZT), 
lamivudine (3TC), stavudine (d4T) and/or tenofovir 
(TDF) combined with either efavirenz (EFV) or 
nevirapine (NVP). Patients also received 
cotrimoxazole prophylaxis as per national guideline. 
Patients were followed up every month for the first 
three or more months until they are clinically stable 
and adherent to their medications, and every three 
month thereafter, or as clinically required. In 
addition, adherence assessment and support, 
nutritional assessment and counseling, risk 
reduction and safe-sex counseling services were 
provided as a routine standard of care during every 
visit and encounter.  
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Patients’ follow-up status was tracked using a 
standard HIV chronic care follow-up form and 
patient appointment calendar. Lost to follow-up was 
defined if patient did not have follow-up visit at 
least 30 days after the last date of the next clinic 
appointment. Lost to follow-up patients tracing was 
done through telephone call or home visit using 
case managers who reported on the status of each 
patient to the data clerks. Transferred out (TO) 
define: if patient moved to another health facility 
with confirmed written documentation of transfer 
out. 
Outcome measure: All-cause mortality was the 
outcome variable; ascertainment of death was from 
death certificates when patients died in hospital, or, 
if patient died in the community, information was 
obtained from participants’ contacts using a 
structured data collection form. 
Statistical analyses:Descriptive analyses of 
patients’ socio-demographic and clinical parameters 
were made. The survival time was calculated in 
months using the time interval between the date of 
ART initiation and date of death, date of lost to 
follow-up, transferred out and completion of 36 
months follow-up. Kaplan-Meier survival analyses 
employed to determine survival probability from the 
time of ART initiation. Participants who terminated 
their follow-up for a reason other than death and 
those who completed their follow-up until 
December 2013 were right-censored. Survival curve 
plotted to estimate survival time to event after ART 
initiation at 6, 12, 18, 24, 30 and 36 months of 
follow-up. A log rank test with p-value < 0.05 level 
of significance was used to compare survival time.   
The Cox proportional hazard regression model was 
used to measure association of baseline predictor 
variables with mortality. Univariate associations of 
each predictor with mortality tested. Those predictor 
variables with significant association on univariate 
analysis (p < 0.05) included in the multivariate 
analysis. However, baseline hemoglobin 
measurement which showed significant association 
on univariate analysis was not included in the 
multivariate analysis for the missing data rate for 
the variable was 31.7%. Shared frailty with gamma 
distribution term fitted to the multivariate model to 
check for homogeneity within site clusters. 
Predictor variables with P-value < 0.05 used for the 
final model.  Results reported in terms of the hazard 
ratios with their 95% confidence intervals and P-
values.  STATA version 12 and SPSS version 21 
were used for the analyses. 
Ethical considerations: Ethical approval was 
obtained from the Ethiopian Public Health Institute, 
the Ethiopian National Ethical Review Committee, 
Johns Hopkins University Institutional Review 
Board (IRB) as well as the Centers for Disease 
Control and Prevention IRB-Atlanta. Patients were 
enrolled after written informed consent. All patients 
were compensated for the time they spent for the 
study and for the inconvenience during blood draw 




Baseline socio-demographic and clinical 
characteristics: A total of 976 newly ART 
initiating PLHIV were included in the analysis. The 
cohort contributed a total of 1,825 person-years of 
follow-up. The median age of the cohort at ART 
initiation was 33 years (range 18-80 years). All 
study subjects were followed for a median of 25 
months (IQR 12-34) on ART.  
Table 1.  Socio-demographic characteristics of 
the study participants on initiation of ART. 
Characteristics  Number (%) 
Participants from Hospital  
   Armed forces  
   Tikur Anbessa 
   Gondar University 
   Jimma Univristy 
   Mekelle 
   Hiwot Fana 
   Hawassa University 











    Male 
    Female 






    18 -25 
    26 -30 
    31-35 
    36-40 
    41-45 
    46-50 
        >51 






83  (8.5) 
65  (6.7) 
45  (4.6) 
976 (100.0) 
Marital status  
    Never married 
    Married 
    Divorced/Separated 
    Widow/widower 







Education    
   No education 
   Primary 
   Secondary 
   Tertiary 
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As seen in Table 1, we found that of 976 patients, 
594 (60.9%) were females, 483 (49.7%) were 
married, and 177 (18.4%) had no formal education.  
The median CD4 count at the start of ART was 144 
cells/µl (interquartile range (IQR) 78-205). Thirty-
four percent of patients had CD4 < 100 cells/µl, and 
63% had viral load greater than 5 log copies/ml. 
Patients ART regimen was efavirenz-based  for 
59.8%   and nevirapine-based for 40.0% of 
patients.% on therapy. Ninty-three percent of 
patients received cotrimoxazole prophylaxis and 
12.8% were on anti-tuberculosis treatment.  
Summary of clinical parameters of patients on 
initiation of ART is shown in table 2. 
 
 
Table 2: Clinical characteristics of study participants at initiation of ART 
 
Survival analyses: A total of 101 (10.3%) deaths 
were recorded during the observation period;all-
cause mortality rate 5.4 /100 person-years of 
observation (PYO), 95% confidence interval 4.4-
6.5. Fifty-three and Seventy percent of the deaths 
occurred during the first three and six months after 
start of ART, respectively.  Of the 875 censored 
cases, 46 (5.2%) were lost to follow-up, and 100 
(11.4%) moved from study areas and transferred-out 
to other health facilities to continue their treatment. 
Figure 1A shows overall survival of the cohort. 
Figure 1B show survival by baseline CD4 strata and 
1C by WHO clinical stage
Characteristics  Number examined  
WHO Stage  
    I & II 
    III & IV 





Hemoglobin   
    <10 gm/dl 
    >10 gm/dl 
   Total 
 




    <100 
    100-199 
  >200 







   <100,000 
   >100,000 






  Efavirenz 
  Nevirapine 





     2 (0.2) 
976 (100.0) 
Cotrimoxazole prophylaxis 
   Yes 
   No  
  Total  
 
909 (93.1) 
67  (6.9) 
976 (100.0) 
TB treatment at initiation   
   Yes 







  Yes 
  No 
  Total 
 
  14 (1.4) 
962 (98.6) 
976 (100.0) 
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1 - A. Kaplan-Meier survival estimates of the cohort 
 
Figure 1B. Survival estimate of the Cohort by CD4 
 
Figure 1C. Survival estimates by WHO clinical stages 
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Risk factors for mortality: The crude and 
adjusted hazard ratios for death are shown in 
Table 2. Age > 51 years, baseline WHO stages 
III/IV, CD4 count < 100 cells/µl, and viral load > 
5 log copies/ml were significant predictors for 
death in both univariate and multivariate analysis. 
 




In recent years, access to ART services for PLHIV 
in Ethiopia is improving; number of health 
facilities which provide ART service has 
increased. However, data from this prospective 
cohort study shows patients were presenting with 
advances clinical stages following infection with 
HIV: 530 (55.3%) of patients with WHO clinical 
III & IV, and 693 (71.8%) with CD4 count < 200 
cells/µl; emphasizing the need to early diagnose, 
link and engage patient into the comprehensive 
ART care program.  
This study showed that age >51 years was an 
independent risk factor for mortality among the 
cohort, similar to several reports from 
industrialized countries (19); but only one study 
from sub-Saharan Africa found such an 
association (20). This may be due to the 
predominantly young age of patients and shorter 
duration of follow-up in resource-limited settings. 
Advanced WHO clinical stages have been 
consistently reported as risk factors for mortality 
in several studies from sub-Saharan Africa (6, 8, 
12, 15, 21-23) as well as the current study, 
reflecting the advanced immunodeficiency at the 
time patients present for treatment. 
Similar to many studies from sub-Saharan Africa, 
low hemoglobin level < 10 gm/dl was a risk factor 
for increased mortality (7, 16, 20, 24, and 25). 
This may be a marker for nutritional deficiency, 
opportunistic infections, cancers, or the effect of 
advanced HIV disease on the hematopoietic 
system. 
Low CD4 count < 100 cells/µl at initiation of 
treatment was strongly associated with increased 
Patient characteristics Crude HR (95% CI   P- Value  Adjusted HR (95% CI)  P-Value 
Sex  
    Male 












    18-25 
    26-30 
    31-35 
    36-40 
    41-45 
    46-50 
    >51 
 
1 
1.11 (0.50 - 2.45) 
1.97 (0.91 - 4.27) 
1.74 (0.79 - 3.82) 
1.79 (0.71 - 4.50) 
2.53 (1.03 – 6.22) 











0.97 (0.43 – 2.17) 
2.09 (0.95 – 4.60) 
1.57 (0.70 – 3.54) 
1.47 (0.55 – 3.91) 
1.93 (0.67 – 5.50) 









WHO Stage  
    I & II 
    III & IV 
 
1 





1.76 (1.07 -2.87) 
 
0.025 
Hemoglobin   
<10 mg /dl 












     <100 
    100-199 
     >200 
 
3.35 (1.90– 5.91) 







2.36 (1.28 – 4.36) 




















Shared frailty  
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mortality, similar to many studies from sub-
Saharan Africa (2, 4-6, 8, 16, 21, 26). Wider 
availability of HIV testing and starting ART at 
higher CD4 counts will prevent many of the early 
on-ART mortality (27, 28). 
In contrast to the current study, viral load was not 
found to be an independent predictor of mortality 
in a meta-analysis of 18 African treatment 
programs (8), probably a reflection of the small 
numbers of patients that had pre-treatment viral 
load measurement in resource-limited settings. 
There was no significant difference in survival 
rate between male and female sexes, unlike other 
studies from resource-poor settings which had 
reported male sex as a risk factor for increased 
mortality (2, 6, 8, 16 -18). However, this finding is 
similar with another study report from Ethiopia, 
(13).   
In Ethiopia, there are few studies that reported on-
ART mortality of HIV-infected adults. At the 
beginning of the ART roll-out in 2006, mortality 
of 16.7/100 PYO was reported from a district 
hospital in South Ethiopia. Most deaths occurred 
within a month of starting treatment, and WHO 
clinical stage IV was a strong predictor of 
mortality (12). The reported mortality was three 
times higher than the current study; this may be 
due to differences in treatment facilities, or to 
improvement of the ART program in later years. 
In an observational study from two district 
hospitals in Oromiya Region that followed 290 
patients for 24 months on ART, an overall 
mortality of 10.3% was reported. However, 
estimates were based on only 28 deaths, and there 
was an 18% loss to follow-up, which 
underestimate the true mortality (13). 
Comparable to the present study, a mortality rate 
of 6.9% was reported among adult patients on 
ART at a tertiary hospital in Addis Ababa; 57% of 
the deaths occurred in the first six months after 
start of ART (14). WHO stage III/IV, CD4 < 50 
cells/µl, and tuberculosis after ART initiation were 
independent risk factors for death 
In the present study, cause-specific mortality was 
not reported because of unavailability of data on 
cause of death. Therefore, the relative 
contributions of advanced immunodeficiency and 
opportunistic infections and cancers to the high 
early on-ART mortality could not be determined. 
Another limitation was that the setting was urban, 
and facilities were university affiliated hospitals 
which may limit generalization to more rural 
settings and lower-level health care facilities. 
The study demonstrated that there was high early 
on-ART mortality which could be reduced by 
wider availability of HIV testing, improved 
package of care services for patients with 
advanced disease and starting treatment before 
advanced immuno-deficiency. 
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